Achieve Life Sciences is a biopharmaceutical company that develops and commercializes therapies that address treatment resistance in cancer patients. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. The Company is also working on cytisine-based therapies as a widely available treatment option for nicotine addiction.

Type
Public
HQ
Bothell, US
Founded
1995
Size (employees)
17 (est)
Achieve Life Sciences was founded in 1995 and is headquartered in Bothell, US
Report incorrect company information

Key People/Management at Achieve Life Sciences

Richard Stewart

Richard Stewart

Chairman and CEO
Scott Cormack

Scott Cormack

Director
John Bencich

John Bencich

EVP, CFO and COO
Jaime Welch

Jaime Welch

EVP, Commercial
Anthony Clarke

Anthony Clarke

President, CSO
Cindy Jacobs

Cindy Jacobs

EVP, CMO

Achieve Life Sciences Office Locations

Achieve Life Sciences has offices in Bothell and Vancouver
Bothell, US (HQ)
19820 North Creek Parkway Suite 201
Vancouver, CA
1001 W. Broadway, Suite 400
Show all (2)
Report incorrect company information

Achieve Life Sciences Financials and Metrics

Achieve Life Sciences Financials

USD

Net income (Q1, 2018)

(3 m)

Market capitalization (25-May-2018)

12.9 m

Closing share price (25-May-2018)

10

Cash (31-Mar-2018)

4.2 m
Achieve Life Sciences's current market capitalization is $12.9 m.
Annual
USDFY, 2013FY, 2016FY, 2017

General and administrative expense

8.9 m3.5 m

R&D expense

14.8 m3.1 m

Operating expense total

23.7 m6.6 m

EBIT

(28.4 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

General and administrative expense

2.5 m2.8 m2.7 m2.5 m2.7 m3.1 m3.1 m2.3 m2.5 m1.9 m2.5 m2.3 m1.8 m

R&D expense

18 m16.9 m9.9 m9.6 m3.7 m6.5 m8.3 m4.6 m4.7 m3.8 m912 k777 k1.2 m

Operating expense total

20.5 m19.7 m12.6 m12 m6.4 m9.6 m11.4 m7.4 m8.5 m4.4 m3.3 m3.1 m3 m

Interest income

33 k12 k4 k3 k54 k13 k24 k48 k61 k53 k27 k23 k10 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

14.6 m27.9 m34.3 m15.2 m5.3 m

Accounts Receivable

218 k113 k111 k32 k

Inventories

Current Assets

53.9 m55.8 m57.3 m26.9 m5.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

13 m28.6 m40.6 m49 m25.3 m48 m42.5 m18.9 m10.6 m11.8 m15.7 m13.9 m4.2 m

Accounts Receivable

295 k166 k19 k71 k76 k48 k53 k47 k36 k32 k32 k

Current Assets

59.7 m48.1 m47.9 m61.3 m45.5 m62.7 m67.6 m48 m41.4 m34.3 m17.5 m14.5 m4.7 m

PP&E

443 k349 k354 k312 k416 k406 k380 k546 k534 k493 k166 k129 k18 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(31.8 m)(26.2 m)(16.8 m)(20.1 m)(10.6 m)

Depreciation and Amortization

227 k223 k244 k188 k59 k

Inventories

Accounts Payable

(1.2 m)(67 k)1.3 m778 k118 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(25.2 m)(8.6 m)(15.7 m)(20.6 m)(4.5 m)(10.5 m)(15.1 m)(3.7 m)(10.6 m)(14.3 m)(3.3 m)(6.3 m)(3 m)

Depreciation and Amortization

162 k55 k110 k165 k46 k116 k178 k56 k103 k148 k93 k130 k86 k

Accounts Payable

(1.3 m)784 k1.2 m1.4 m916 k230 k1.7 m(751 k)(784 k)(300 k)(1.8 m)(1.9 m)207 k

Cash From Operating Activities

(6.4 m)10.2 m1.6 m(15.4 m)(22.7 m)(9 m)(11.5 m)(2.2 m)
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information